Soon after families carve up the Thanksgiving turkey, the US IPO market will see its own large carve-outs. Spin-offs have been a recurring theme over the past couple years, and recent filings from ZEEKR (ZK) and UL Solutions (ULS) signal that the trend is set to continue. Compared to VC- or PE-backed deals, carve-out IPOs are more prevalent...read more
In what would be the largest US IPO since late 2021, Kenvue (KVUE) is slated to raise $3.3 billion, more than doubling YTD IPO proceeds. It's scheduled to begin trading this week. Being spun out of Johnson & Johnson, consumer health giant Kenvue is pitching a mature and profitable...read more
The IPO Market Flips from Boom to Bust in 2022 After the prior year’s record activity, the 2022 US IPO market ground to a halt as the war in Ukraine, a valuation correction in high-multiple stocks, historic interest rate hikes, and looming fears of a recession caused the narrowing IPO window to slam shut. 71...read more
IPO Market Misfires in the Slowest 3Q in Over a Decade It was the worst third quarter for new issuers in over a decade, with 25 IPOs raising $2.4 billion as the 2022 US IPO market remains on track to raise the lowest proceeds of any year in our firm's 30+ year history. While issuance did pick up slightly from the...read more
IPO investors crave carve-outs with 2 more teed up after Thanksgiving
Soon after families carve up the Thanksgiving turkey, the US IPO market will see its own large carve-outs. Spin-offs have been a recurring theme over the past couple years, and recent filings from ZEEKR (ZK) and UL Solutions (ULS) signal that the trend is set to continue. Compared to VC- or PE-backed deals, carve-out IPOs are more prevalent...read more
Kenvue is the IPO market's latest spin-off; here's how past spin-offs have performed alongside former parents
In what would be the largest US IPO since late 2021, Kenvue (KVUE) is slated to raise $3.3 billion, more than doubling YTD IPO proceeds. It's scheduled to begin trading this week. Being spun out of Johnson & Johnson, consumer health giant Kenvue is pitching a mature and profitable...read more
Updated: Renaissance Capital's 2022 US IPO Market Review
The IPO Market Flips from Boom to Bust in 2022 After the prior year’s record activity, the 2022 US IPO market ground to a halt as the war in Ukraine, a valuation correction in high-multiple stocks, historic interest rate hikes, and looming fears of a recession caused the narrowing IPO window to slam shut. 71...read more
Updated: Renaissance Capital's 3Q 2022 US IPO Market Review
IPO Market Misfires in the Slowest 3Q in Over a Decade It was the worst third quarter for new issuers in over a decade, with 25 IPOs raising $2.4 billion as the 2022 US IPO market remains on track to raise the lowest proceeds of any year in our firm's 30+ year history. While issuance did pick up slightly from the...read more